Discover open access scientific publications

Search, annotate, share and cite publications

Publications by H. Holte

Low Levels of Monoclonal Small B Cells in the Bone Marrow of Patients With Diffuse Large B-Cell Lymphoma of Activated B-Cell Type but Not of Germinal Center B-Cell Type

Haematologica

Hematology

2010

English

A Phase 1/2 Study of Pixantrone, Etoposide, Bendamustine And, in Cd20+ Tumors, Rituximab in Patients With Relapsed Aggressive B- Or T-Cell Lymphomas-The P[r]eben Study

Hematological Oncology

English

Young High Risk Patients With Diffuse Large B-Cell Lymphoma Including BCL-2/Myc Double Hit Lymphomas Benefit From Dose-Dense Immunochemotherapy With Early CNS Prophylaxis

Hematological Oncology

English

Prognostic Value of Baseline FDG Pet Parameters in High Risk Diffuse Large B-Cell Lymphoma Patients

Hematological Oncology

English

Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial

Hematological Oncology

English

Global Pivotal Phase 2 Trial of the Cd19-Targeted Therapy Ctl019 in Adult Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)-An Interim Analysis

Hematological Oncology

English

Clinical Significance of T-Cell Exhaustion in Patients With Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Reduced Sexual Function in Long-Term Male Lymphoma Survivors After High Dose Therapy With Autologous Stem Cell Transplantation

Hematological Oncology

English

Dose-Dense Chemoimmunotherapy and CNS Prophylaxis in Patients With High-Risk Dlbcl: A Comparison of Nordic Cry-04 and Chic Studies

Hematological Oncology

English

Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by H. Holte

Low Levels of Monoclonal Small B Cells in the Bone Marrow of Patients With Diffuse Large B-Cell Lymphoma of Activated B-Cell Type but Not of Germinal Center B-Cell Type

A Phase 1/2 Study of Pixantrone, Etoposide, Bendamustine And, in Cd20+ Tumors, Rituximab in Patients With Relapsed Aggressive B- Or T-Cell Lymphomas-The P[r]eben Study

Young High Risk Patients With Diffuse Large B-Cell Lymphoma Including BCL-2/Myc Double Hit Lymphomas Benefit From Dose-Dense Immunochemotherapy With Early CNS Prophylaxis

Prognostic Value of Baseline FDG Pet Parameters in High Risk Diffuse Large B-Cell Lymphoma Patients

Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial

Global Pivotal Phase 2 Trial of the Cd19-Targeted Therapy Ctl019 in Adult Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)-An Interim Analysis

Clinical Significance of T-Cell Exhaustion in Patients With Diffuse Large B-Cell Lymphoma

Reduced Sexual Function in Long-Term Male Lymphoma Survivors After High Dose Therapy With Autologous Stem Cell Transplantation

Dose-Dense Chemoimmunotherapy and CNS Prophylaxis in Patients With High-Risk Dlbcl: A Comparison of Nordic Cry-04 and Chic Studies

Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients